-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
May 2021
-
Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC
Despite U.S. Food and Drug Administration (FDA) approvals for the addition of anti–programmed death-ligand 1 (PD-L1) therapies to a first-line combination of etoposide plus a platinum-based agent for extensive-stage small cell lung cancer (SCLC).1 ,2 Overall survival (OS) remains poor—roughly 1 year for patients diagnosed with extensive-stage disease. Promising new agents in relapsed disease, such…
-
Survivorship in Lung Cancer: An Interview With Dr. Anne Katz
Anne Katz, PhD, RN, FAAN, is a certified sexuality counselor and clinical nurse specialist at Cancer Care Manitoba, Winnipeg, Canada, and the author of multiple books on cancer survivorship. In the following article, Dr. Katz discusses lung cancer survivorship challenges as well as considerations that providers should take to ensure that this population is receiving…
-
Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?
October 2, 2020, saw the first U.S. Food and Drug Administration approval of a drug combination for malignant pleural mesothelioma in 16 years, since the combination cisplatin and pemetrexed was approved for this indication in 2004. During the intervening years, we have witnessed numerous negative clinical trials of drug combinations for this disease, mostly phase…
-
Wally Curran Departs Directorship at Emory for a Lead Role with GenesisCare
Walter J. “Wally” Curran, Jr., MD, the first radiation oncologist to serve as director of a National Cancer Institute-designated comprehensive cancer center, stepped down from that role at Emory University’s Winship Cancer Institute in January 2021 to take the reins as global chief medical officer of GenesisCare, which provides radiation oncology, urology, and pulmonary treatments…
-
Dr. Anne-Marie Dingemans Leads EORTC’s Lung Cancer Group
Anne-Marie Dingemans, MD, PhD, was installed in January 2021 as chair of the European Organisation for Research and Treatment of Cancer Lung Cancer Group, filling a role previously held by Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Campus in Paris. Dr. Dingemans has been a pulmonologist and professor at Erasmus Medical Center in…
-
Dr. Marina Garassino Accepts Professorship at University of Chicago
Marina Chiara Garassino, MD, stepped into a role as professor of medicine in the Section of Hematology/Oncology at the University of Chicago Department of Medicine in March 2021, making a move from one of the most renowned comprehensive cancer centers in Italy, the Istituto Nazionale dei Tumori of Milan, where she led the Thoracic Medical Oncology…
-
Leveraging Lung Cancer Screening Scans to Detect Early Interstitial and Obstructive Lung Disease
CT screening for lung cancer can reveal subtle early signs of disease in the lungs that extend beyond potential malignancy. As reviewed by Bram van Ginneken, PhD, of the Radboud University Medical Center in The Netherlands, quantitative measures obtained from a chest CT scan may enable the early detection of different obstructive and interstitial lung…
-
Low-Dose CT Screening with Guidance from Biomarkers May be Beneficial for Some Patients Who Have Never Smoked
Although about 20% of those who die of lung cancer in the United States each year have never smoked,1 only individuals with heavy smoking histories are eligible for low-dose CT screening that can identify disease at an early stage, when curative treatment may be possible. As never-smoking populations grow in the United States and Europe,…
-
Strategies for Implementing Lung Cancer Screening Programs in Low-Middle Income Countries
A wide range of nations at various stages of economic and health-system development fall under the umbrella of low- and middle-income countries (LIMC). As Lucía Viola, MD, of the Fundación Neumológica Colombiana in Bogota, Colombia, explained during a talk in which she addressed lung cancer screening implementation in these countries, LMIC “comprises regions where communicable…
-
Low-Dose CT Could be One-Stop Test for Early Signs of China’s ‘Big Three’ Chest Diseases
Finding one effective test for the three chest conditions that are the leading causes of death in China, without a high risk of false positives, would allow better control of the mortality rate by expanding opportunities for early treatment. Researchers at three hospitals in China and one in the Netherlands are conducting the NELCIN B3…